Merck (NYSE: MRK), known as MSD outside the United States and Canada, has presented promising results from its Phase 2 waveLINE-007 trial at the 66th American Society of Hematology (ASH) Annual Meeting. The trial evaluated zilovertamab vedotin, an investigational antibody-drug…
ReAlta Life Sciences, Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, announced promising preclinical data for its lead asset, RLS-0071 (pegtarazimod), in acute Graft-versus-Host Disease (aGVHD). These findings will…
Genmab A/S has shared new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) for treating relapsed or refractory (R/R) follicular lymphoma (FL). The study demonstrated an…
Orca Bio, a late-stage biotechnology company focused on transforming patient care through high-precision cell therapy, presented clinical findings today at the 66th American Society of Hematology (ASH) Annual Meeting. The data highlights the use of Orca-Q, its investigational second-generation allogeneic…
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will present new findings at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. The data demonstrates that a donor search prognosis score enables physicians to expedite…
AstraZeneca has announced that its supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review. This application aims to expand the treatment options for patients with muscle-invasive bladder…
Aaron Nagiel, MD, PhD, a leading pediatric retinal specialist at Children’s Hospital Los Angeles (CHLA), often hears stories from parents long after their child’s retinal gene therapy treatment. These heartfelt updates highlight significant improvements, such as a toddler seeing animals…
Alithea Genomics, a leader in RNA sequencing and transcriptomics, has introduced its MERCURIUS™ Full-Length DRUG-seq library preparation technology. This groundbreaking innovation combines massive sample multiplexing, an extraction-free workflow, and full transcript coverage, creating a unique RNA-seq workflow. The technology is…
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into a strategic partnership to investigate the potential of IPH6501, Innate’s anti-CD20 ANKET® (Antibody-based NK cell Engager Therapeutics), in the treatment of…
A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials demonstrated that datopotamab deruxtecan (Dato-DXd) achieved significant clinical responses in patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). These findings, including progression-free…